{"id":"NCT01304498","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)","officialTitle":"A Randomized, Double-Blinded, Controlled With GARDASIL (Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, Adsorbed)), Phase III Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus (HPV) Vaccine) in Preadolescent and Adolescent Girls (9- to 15-year-old)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02-23","primaryCompletion":"2011-12-20","completion":"2011-12-20","firstPosted":"2011-02-25","resultsPosted":"2017-08-22","lastUpdate":"2018-12-14"},"enrollment":600,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Human Papillomavirus"],"interventions":[{"type":"BIOLOGICAL","name":"V503","otherNames":["9vHPV vaccine"]},{"type":"BIOLOGICAL","name":"GARDASIL","otherNames":["qHPV vaccine"]}],"arms":[{"label":"V503","type":"EXPERIMENTAL"},{"label":"GARDASIL","type":"ACTIVE_COMPARATOR"}],"summary":"Primary objective:\n\nâ€¢ To demonstrate that administration of V503 induces non-inferior Geometric Mean Titers (GMTs) (for serum anti-HPV16 and anti-HPV18) compared to GARDASIL.\n\nSecondary objectives:\n\n* To evaluate the tolerability of V503 in 9-15 year-old girls.\n* To summarize humoral immune response (anti-HPV 6, 11, 16, 18) induced by V503 or GARDASIL.","primaryOutcome":{"measure":"Geometric Mean Titers (GMTs) to HPV Types 16 and 18","timeFrame":"4 weeks postdose 3 (Month 7)","effectByArm":[{"arm":"V503","deltaMin":6739.5,"sd":null},{"arm":"GARDASIL","deltaMin":6887.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"9 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":10},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["26090572","27422279"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":299},"commonTop":["Injection-site pain","Injection-site swelling","Injection-site erythema","Headache","Pyrexia"]}}